<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Dement Neuropsychol</journal-id><journal-id journal-id-type="pmc-domain-id">3245</journal-id><journal-id journal-id-type="pmc-domain">dementneuro</journal-id><journal-id journal-id-type="publisher-id">dn</journal-id><journal-title-group><journal-title>Dementia &amp; Neuropsychologia</journal-title></journal-title-group><issn pub-type="ppub">1980-5764</issn><issn pub-type="epub">2764-4863</issn><publisher><publisher-name>Academia Brasileira de Neurologia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10229084</article-id><article-id pub-id-type="pmcid-ver">PMC10229084.1</article-id><article-id pub-id-type="pmcaid">10229084</article-id><article-id pub-id-type="pmcaiid">10229084</article-id><article-id pub-id-type="pmid">37261259</article-id><article-id pub-id-type="doi">10.1590/1980-5764-DN-2022-0048</article-id><article-id pub-id-type="other">00202</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>View &amp; Review</subject></subj-group></article-categories><title-group><article-title>Proton pump inhibitors and dementia: what association?</article-title><trans-title-group xml:lang="pt"><trans-title>Inibidores da bomba de prot&#245;es e dem&#234;ncia: que associa&#231;&#227;o?</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3325-179X</contrib-id><name name-style="western"><surname>Caetano</surname><given-names initials="C">Catarina</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">investigation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">methodology</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">project administration</role><role content-type="http://credit.niso.org/contributor-roles/resources/">resources</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">supervision</role><role content-type="http://credit.niso.org/contributor-roles/validation/">validation</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">visualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">writing &#8211; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">writing &#8211; review &amp; editing (lead)</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2151-7039</contrib-id><name name-style="western"><surname>Veloso</surname><given-names initials="M">Marta</given-names></name><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">investigation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">methodology</role><role content-type="http://credit.niso.org/contributor-roles/validation/">validation</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">writing &#8211; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">writing &#8211; review &amp; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9641-7083</contrib-id><name name-style="western"><surname>Borda</surname><given-names initials="S">Susana</given-names></name><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">investigation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">methodology</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">visualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">writing &#8211; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">writing &#8211; review &amp; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><aff id="aff1">
<label>1</label>Unidade de Sa&#250;de Familiar Delta, Administra&#231;&#227;o Regional de Sa&#250;de de Lisboa e Vale do Tejo, Oeiras, Lisboa, Portugal.</aff></contrib-group><author-notes><corresp id="c1"><bold>Correspondence:</bold> Catarina Caetano; Email: <email>catarinammcaetano@gmail.com</email>.</corresp><fn fn-type="COI-statement"><p>
<bold>Disclosure:</bold> The authors report no conflicts of interest.</p></fn></author-notes><pub-date date-type="pub" publication-format="electronic"><day>29</day><month>5</month><year>2023</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2023</year></pub-date><volume>17</volume><issue-id pub-id-type="pmc-issue-id">436320</issue-id><elocation-id>e20220048</elocation-id><history><date date-type="received"><day>10</day><month>8</month><year>2022</year></date><date date-type="rev-recd"><day>31</day><month>12</month><year>2022</year></date><date date-type="accepted"><day>20</day><month>1</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>05</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>31</day><month>05</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-26 19:25:27.387"><day>26</day><month>06</month><year>2024</year></date></event></pub-history><permissions><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="1980-5764-DN-17-e20220048.pdf"/><abstract><title>ABSTRACT.</title><p>Several recent studies have suggested an association between proton pump inhibitors and the development of cognitive changes.</p><sec><title>Objective:</title><p>To assess the existence of this association.</p></sec><sec><title>Methods:</title><p>A comprehensive literature search was conducted including guidelines, meta-analyses, systematic reviews, observational and experimental studies published between February 2011 and February 2021.</p></sec><sec><title>Results:</title><p>The initial research identified 393 articles, 28 of which were included: 8 systematic reviews, 1 clinical trial, 15 observational studies, 3 case-control studies, and 1 cross-sectional observational study.</p></sec><sec><title>Conclusions:</title><p>Most studies classified with the highest level of evidence found no statistically significant association between the use of proton pump inhibitors and the development of cognitive impairment or dementia.</p></sec></abstract><trans-abstract xml:lang="pt"><title>RESUMO.</title><p>Nos &#250;ltimos anos, t&#234;m sido publicados v&#225;rios estudos que indicam uma associa&#231;&#227;o entre o uso de inibidores da bomba de prot&#245;es e o desenvolvimento de altera&#231;&#245;es cognitivas.</p><sec><title>Objetivo:</title><p>Avaliar a exist&#234;ncia desta associa&#231;&#227;o.</p></sec><sec><title>M&#233;todos:</title><p>Foi realizada uma pesquisa bibliogr&#225;fica abrangente, incluindo diretrizes, meta-an&#225;lises, revis&#245;es sistem&#225;ticas, estudos experimentais e observacionais publicados entre fevereiro de 2011 e de 2021.</p></sec><sec><title>Resultados:</title><p>A pesquisa inicial identificou 393 artigos, dos quais 28 foram inclu&#237;dos: 8 revis&#245;es sistem&#225;ticas, 1 ensaio cl&#237;nico, 15 estudos observacionais, 3 estudos de caso-controle e 1 estudo observacional transversal.</p></sec><sec><title>Conclus&#245;es:</title><p>A maioria dos estudos com o maior n&#237;vel de evid&#234;ncia n&#227;o encontrou uma associa&#231;&#227;o estatisticamente significativa entre o uso de inibidores da bomba de prot&#245;es e o desenvolvimento de d&#233;fice cognitivo ou dem&#234;ncia.</p></sec></trans-abstract><kwd-group><title>Keywords:</title><kwd>Proton Pump Inhibitors</kwd><kwd>Dementia</kwd><kwd>Cognitive Dysfunction</kwd></kwd-group><kwd-group xml:lang="pt"><title>Palavras-chave:</title><kwd>Inibidores da Bomba de Pr&#243;tons</kwd><kwd>Dem&#234;ncia</kwd><kwd>Disfun&#231;&#227;o Cognitiva</kwd></kwd-group><counts><fig-count count="1"/><table-count count="3"/><equation-count count="0"/><ref-count count="48"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Proton pump inhibitors (PPIs) have been central to the management of acid-related upper gastrointestinal disorders for the past three decades<sup>
<xref rid="B1" ref-type="bibr">1</xref>
</sup>.</p><p>PPIs are among the most commonly prescribed drugs worldwide. Up to 1 in 5 older adults takes PPIs &#8211; and frequently &#8211; on a long-term basis<sup>
<xref rid="B2" ref-type="bibr">2</xref>
</sup>.</p><p>Various studies worldwide have pointed to the inappropriate prescription of these drugs, either in excessive dosage, inappropriate prolonged duration, or in the absence of medical recommendation<sup>
<xref rid="B3" ref-type="bibr">3</xref>&#8211;<xref rid="B5" ref-type="bibr">5</xref>
</sup>.</p><p>Along with the generalization of its use, there has been a growing concern about its adverse effects, widely disseminated through the media. Published scientific evidence on the safety profile of these drugs supports an association between long-term use of PPIs and an increased risk of developing acute and chronic kidney disease, Clostridium difficile infection, community-acquired pneumonia, bone fractures, hypomagnesemia, vitamin B12 deficiency, among others<sup>
<xref rid="B6" ref-type="bibr">6</xref>&#8211;<xref rid="B9" ref-type="bibr">9</xref>
</sup>.</p><p>These effects are more pronounced among the elderly, for which the American Geriatrics Society Beers Criteria, updated in 2019, advise against the use of PPIs for more than 8 weeks, except in situations of erosive esophagitis, Barrett esophagus, hypersecretory pathology or demonstrated need for treatment maintenance<sup>
<xref rid="B10" ref-type="bibr">10</xref>
</sup>.</p><p>In recent years, some studies have suggested an association between the use of PPIs and the development of cognitive impairment<sup>
<xref rid="B11" ref-type="bibr">11</xref>&#8211;<xref rid="B13" ref-type="bibr">13</xref>
</sup>.</p><p>Several mechanisms have been proposed to explain the possible association between PPIs use and the development of dementia<sup>
<xref rid="B14" ref-type="bibr">14</xref>&#8211;<xref rid="B17" ref-type="bibr">17</xref>
</sup>. One of the mechanisms focuses on the decrease in vitamin B12, which has been associated with cognitive decline and neurological damage<sup>
<xref rid="B18" ref-type="bibr">18</xref>
</sup>, probably due to decreased synthesis of deoxyribonucleic acid and homocysteine neurotoxicity<sup>
<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B20" ref-type="bibr">20</xref>
</sup>. There is evidence that PPIs (e.g. lansoprazole and omeprazole) cross the blood-brain barrier; therefore, several intracerebral mechanisms have been studied<sup>
<xref rid="B21" ref-type="bibr">21</xref>,<xref rid="B22" ref-type="bibr">22</xref>
</sup>. A possible factor for the effect of PPIs on cognition is through direct interaction with brain enzymes. A recent study by Badiola et al. found that PPIs, such as lansoprazole, increase levels of amyloid beta peptide (A&#946;) in an amyloid cell model and in the mouse brain<sup>
<xref rid="B23" ref-type="bibr">23</xref>
</sup>. A&#946; peptides are one of the main pathological signs of Alzheimer's disease and are also cytotoxic to endothelial cells<sup>
<xref rid="B14" ref-type="bibr">14</xref>
</sup>. Another mechanism described for the increase in A&#946; peptide deposits by PPIs refers to the possible modulation of their degradation by lysosomes in microglia, since this process is pH-dependent and induced by lysosome acidification. This acidification has been described as mediated by the vacuolar proton pump adenosine triphosphatase and it is thought that PPIs will have an inhibitory action on these and may contribute to the inhibition of A&#946; degradation and thus increase its deposit<sup>
<xref rid="B24" ref-type="bibr">24</xref>&#8211;<xref rid="B26" ref-type="bibr">26</xref>
</sup>.</p><p>This review aimed to assess whether there is an association between the use of PPIs and the development of cognitive impairment or dementia, according to the currently available scientific evidence.</p></sec><sec sec-type="methods"><title>METHODS</title><p>The authors performed a literature search of meta-analyses, systematic reviews, randomized controlled trials, cohort studies, case-control studies, and guidelines published in the following databases: PubMed, Cochrane Library, Database of Abstracts of Reviews of Effects, Guidelines Finder, Canadian Medical Association Infobase e National Guidelines Clearinghouse.</p><p>We used the following MeSH terms: PPI, PPIs, proton pump inhibitors, omeprazole, pantoprazole, esomeprazole, lansoprazole or rabeprazole and cognitive impairment or dementia.</p><p>Articles published between 02/18/2011 and 02/18/2021, in English, Portuguese or Spanish, that met the following criteria were included in the review:</p><list list-type="bullet"><list-item><p>Population: adults without a previous diagnosis of mild cognitive impairment or dementia;</p></list-item><list-item><p>Intervention: use of PPIs;</p></list-item><list-item><p>Control: placebo, H2 receptor antagonists, or no drug; and</p></list-item><list-item><p>Outcome: development of mild cognitive impairment or dementia. Repeated articles and those that did not meet the eligibility criteria and purpose of the review were excluded.</p></list-item></list><p>For article selection, the authors proceeded to three phases of exclusion: regarding the title, level of evidence classification of each article, and strength of the abstract. Afterwards, the full article was read. Each one was read by two authors, resorting to the third in situations of disagreement between the first two.</p><p>The methods for the diagnosis of dementia were heterogeneous. In some studies, the diagnosis of dementia was based on cognitive tests (e.g., Mini-Mental State Examination [MMSE], Clock Drawing Test [CDT] or Abbreviated Mental Test [7-Minute Screen]), brain imaging (computed tomography [CT], magnetic resonance imaging [MRI], or single-photon emission computed tomography [SPECT]), and dementia symptoms. Often the diagnosis was confirmed by a board-certified psychiatrist or neurologist, based on the criteria of Diagnostic and Statistical Manual of Mental Disorders (DMS)-IV. In other studies, the authors assumed the diagnosis as documented based on the International Classification of Diseases (ICD) codes or prescription records for medication for treating dementia.</p><p>The association of dementia and use of PPIs could have been assessed as categorical variables, such as adjusted hazard ratio (HR) and adjusted odds ratio (OR) or relative risk (RR).</p><p>Some studies used adjusted ratios (i.e., those that adjusted for most factors).</p><p>Strength of Recommendation Taxonomy (SORT) system was used.</p></sec><sec sec-type="results"><title>RESULTS</title><p>From the initial search, 393 articles were obtained. After the selection process (<xref rid="f1" ref-type="fig">Figure 1</xref>), 28 articles were included in the review: 8 systematic reviews (7 of them with meta-analysis), 1 randomized clinical trial, 15 cohort studies, 3 case-control studies, and 1 cross-sectional observational study.</p><fig position="float" id="f1" orientation="portrait"><label>Figure 1</label><caption><title>Article selection process.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="1980-5764-DN-17-e20220048-gf01.jpg"/></fig><sec><title>Clinical trials</title><p>A single randomized clinical trial was identified, which compared the use of pantoprazole 40 mg versus (vs.) placebo in patients with atherosclerotic disease (<xref rid="t1" ref-type="table">Table 1</xref>)<sup>
<xref rid="B27" ref-type="bibr">27</xref>
</sup>. The group of patients using pantoprazole presented an OR of 1.20 and 95% confidence interval (CI) 0.81&#8211;1.78 for the development of dementia, without statistical significance<sup>
<xref rid="B27" ref-type="bibr">27</xref>
</sup>.</p><table-wrap position="float" id="t1" orientation="portrait"><label>Table 1</label><caption><title>Clinical trials.</title></caption><table frame="hsides" rules="rows"><colgroup width="12%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000"><tr style="background-color:#126CA2;"><th align="left" valign="middle" rowspan="1" colspan="1">Author, year</th><th align="center" valign="middle" rowspan="1" colspan="1">Type of study</th><th align="center" valign="middle" rowspan="1" colspan="1">Sample size</th><th align="center" valign="middle" rowspan="1" colspan="1">Intervention</th><th align="center" valign="middle" rowspan="1" colspan="1">Outcome</th><th align="center" valign="middle" rowspan="1" colspan="1">Results</th><th align="center" valign="middle" rowspan="1" colspan="1">Conclusion</th><th align="center" valign="middle" rowspan="1" colspan="1">LE</th></tr></thead><tbody style="border-bottom: thin solid; border-color: #000000"><tr style="background-color:#ECEFF7"><td align="left" valign="middle" rowspan="1" colspan="1">Moayyedi et al.<sup>
<xref rid="B27" ref-type="bibr">27</xref>
</sup>, 2019</td><td align="center" valign="middle" rowspan="1" colspan="1">Multicenter double-blind randomized controlled trial</td><td align="center" valign="middle" rowspan="1" colspan="1">17,598</td><td align="center" valign="middle" rowspan="1" colspan="1">Pantoprazole 40 mg vs. placebo in patients with atherosclerotic disease</td><td align="center" valign="middle" rowspan="1" colspan="1">Secondary: Dementia diagnosis in the follow-up period (3 years)</td><td align="center" valign="middle" rowspan="1" colspan="1">OR=1.2; 95%CI (0.81&#8211;1.78) (p=0.36)</td><td align="center" valign="middle" rowspan="1" colspan="1">No association</td><td align="center" valign="middle" rowspan="1" colspan="1">I</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>Abbreviations: LE: level of evidence; OR: odds ratio; CI: confidence interval; p: p-value.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Observational studies</title><sec><title>Longitudinal studies</title><p>The literature search yielded six prospective and nine retrospective cohort studies (<xref rid="t2" ref-type="table">Table 2</xref>)<sup>
<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B27" ref-type="bibr">27</xref>&#8211;<xref rid="B42" ref-type="bibr">42</xref>
</sup>. Two of the prospective studies<sup>
<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B15" ref-type="bibr">15</xref>
</sup> found an increased risk of developing dementia associated with PPI use, both conducted in Germany. Haenisch et al.<sup>
<xref rid="B14" ref-type="bibr">14</xref>
</sup> evaluated the effect of using any PPI compared with no use of these drugs in a population aged 75 years and over, with a HR of 1.38 for all-cause dementia and 1.44 for Alzheimer's disease.</p><table-wrap position="float" id="t2" orientation="portrait"><label>Table 2</label><caption><title>Observational studies.</title></caption><table frame="hsides" rules="rows"><colgroup width="8%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000"><tr><th align="left" rowspan="2" valign="middle" colspan="1"/><th align="center" style="background-color:#126CA2; border-left: thin solid; border-color: #000000;" valign="middle" rowspan="1" colspan="1">LE</th><th align="center" style="background-color:#126CA2;" valign="middle" rowspan="1" colspan="1">I</th><th align="center" style="background-color:#126CA2;" valign="middle" rowspan="1" colspan="1">I</th><th align="center" style="background-color:#126CA2;" valign="middle" rowspan="1" colspan="1">II</th><th align="center" style="background-color:#126CA2;" valign="middle" rowspan="1" colspan="1">I</th><th align="center" style="background-color:#126CA2;" valign="middle" rowspan="1" colspan="1">I</th><th align="center" style="background-color:#126CA2;" valign="middle" rowspan="1" colspan="1">I</th><th align="center" colspan="2" style="background-color:#126CA2;" valign="middle" rowspan="1">II</th><th align="center" style="background-color:#126CA2;" valign="middle" rowspan="1" colspan="1">II</th><th align="center" style="background-color:#126CA2;" valign="middle" rowspan="1" colspan="1">II</th></tr><tr style="background-color:#ECEFF7"><th align="center" style="border-left: thin solid; border-color: #000000;" valign="middle" rowspan="1" colspan="1">Conclusion</th><th align="center" valign="middle" rowspan="1" colspan="1">Increased risk</th><th align="center" valign="middle" rowspan="1" colspan="1">Increased risk</th><th align="center" valign="middle" rowspan="1" colspan="1">Risk reduction</th><th align="center" valign="middle" rowspan="1" colspan="1">No association</th><th align="center" valign="middle" rowspan="1" colspan="1">No association</th><th align="center" valign="middle" rowspan="1" colspan="1">No association</th><th align="center" colspan="2" valign="middle" rowspan="1">Increased risk</th><th align="center" valign="middle" rowspan="1" colspan="1">No association</th><th align="center" valign="middle" rowspan="1" colspan="1">No association</th></tr></thead><tbody style="border-bottom: thin solid; border-color: #000000"><tr style="background-color:#ECEFF7"><td align="left" rowspan="6" style="background-color:#ECEFF7" valign="middle" colspan="1">Observational studies</td><td align="center" style="border-left: thin solid; border-color: #000000;" valign="middle" rowspan="1" colspan="1">Results</td><td align="center" valign="middle" rowspan="1" colspan="1">ACD: HR=1.38; 95%CI (1.04&#8211;1.8); AD: HR=1.44; 95%CI (1.01&#8211;2.06)</td><td align="center" valign="middle" rowspan="1" colspan="1">HR=1.44; 95%CI (1.36&#8211;1.52) (p&lt;0.001)</td><td align="center" valign="middle" rowspan="1" colspan="1">From normal cognition: HR=0.78; 95%CI (0.66&#8211;0.93) (p=0.005)Progression from MCI to Dementia: HR=0.82; 95%CI (0.69&#8211;0.98) (p=0.03)</td><td align="center" valign="middle" rowspan="1" colspan="1">ACD: OR=1.13 (p=0.67)AD: OR=1.11 (p=0.77). Cumulative doses of: 365 TSDDs, 1,095 TSDDs and 1,825 TSDDs: HRs without statistical significance.</td><td align="center" valign="middle" rowspan="1" colspan="1">Mean score differences from 0.00 to &#8722;0.06 points for periods of PPI use between 1 to 14 years. p&#8805;0.84</td><td align="center" valign="middle" rowspan="1" colspan="1">HR=0.99, 95%CI (0.70&#8211;1.37)</td><td align="center" colspan="2" valign="middle" rowspan="1">Dementia diagnosis: aSR=1.21;95%CI (1.16&#8211;1.27). Use of anti-dementia drugs: aSR=1.38 95%CI (1.28&#8211;1.48)</td><td align="center" valign="middle" rowspan="1" colspan="1">Elderly PPI users vs. non-users: difference of &#8722;1.22 points, 95%CI (&#8722;3.73&#8211;1.29) Individuals 46-67 years old PPI users vs. non-users: difference of 0.94 points, 95%CI (&#8722;1.63&#8211;3.50)</td><td align="center" valign="middle" rowspan="1" colspan="1">Prolonged use of PPIs: HR=0.99, 95%CI (0.93&#8211;1.17) Intermittent use of PPIs: HR=0.91, 95%CI (0.76&#8211;1.09)</td></tr><tr style="background-color:#ECEFF7"><td align="center" style="border-left: thin solid; border-color: #000000;" valign="middle" rowspan="1" colspan="1">Outcome</td><td align="center" valign="middle" rowspan="1" colspan="1">Diagnosis of all-cause dementia or Alzheimer's disease</td><td align="center" valign="middle" rowspan="1" colspan="1">Dementia diagnosis</td><td align="center" valign="middle" rowspan="1" colspan="1">Diagnosis of LBD (Lewy Bodies Dementia)Dementia from normal cognition or diagnosis of dementia in patients with LBD.</td><td align="center" valign="middle" rowspan="1" colspan="1">Diagnosis of all-cause dementia or Alzheimer's disease</td><td align="center" valign="middle" rowspan="1" colspan="1">Neurocognitive assessment performance</td><td align="center" valign="middle" rowspan="1" colspan="1">Dementia diagnosis</td><td align="center" colspan="2" valign="middle" rowspan="1">Dementia diagnosis or prescription of anti-dementia drugs</td><td align="center" valign="middle" rowspan="1" colspan="1">Neurocognitive assessment performance</td><td align="center" valign="middle" rowspan="1" colspan="1">Dementia diagnosis</td></tr><tr style="background-color:#ECEFF7"><td align="center" style="border-left: thin solid; border-color: #000000;" valign="middle" rowspan="1" colspan="1">Intervention</td><td align="center" valign="middle" rowspan="1" colspan="1">PPIs use</td><td align="center" valign="middle" rowspan="1" colspan="1">PPIs use</td><td align="center" valign="middle" rowspan="1" colspan="1">PPIs use</td><td align="center" valign="middle" rowspan="1" colspan="1">PPIs use (cumulative dose)</td><td align="center" valign="middle" rowspan="1" colspan="1">PPIs use</td><td align="center" valign="middle" rowspan="1" colspan="1">Cumulative dose PPIs vs. H2 blockers</td><td align="center" colspan="2" valign="middle" rowspan="1">PPIs use</td><td align="center" valign="middle" rowspan="1" colspan="1">PPIs use</td><td align="center" valign="middle" rowspan="1" colspan="1">PPIs use</td></tr><tr style="background-color:#ECEFF7"><td align="center" style="border-left: thin solid; border-color: #000000;" valign="middle" rowspan="1" colspan="1">Sample</td><td align="center" valign="middle" rowspan="1" colspan="1">3,076</td><td align="center" valign="middle" rowspan="1" colspan="1">73,679</td><td align="center" valign="middle" rowspan="1" colspan="1">10,486</td><td align="center" valign="middle" rowspan="1" colspan="1">3,484</td><td align="center" valign="middle" rowspan="1" colspan="1">13,864</td><td align="center" valign="middle" rowspan="1" colspan="1">70,529</td><td align="center" colspan="2" valign="middle" rowspan="1">1,000,000</td><td align="center" valign="middle" rowspan="1" colspan="1">7,878</td><td align="center" valign="middle" rowspan="1" colspan="1">10,533</td></tr><tr style="background-color:#ECEFF7"><td align="center" style="border-left: thin solid; border-color: #000000;" valign="middle" rowspan="1" colspan="1">Type of study</td><td align="center" valign="middle" rowspan="1" colspan="1">Prospective cohort</td><td align="center" valign="middle" rowspan="1" colspan="1">Prospective cohort</td><td align="center" valign="middle" rowspan="1" colspan="1">Retrospective cohort</td><td align="center" valign="middle" rowspan="1" colspan="1">Prospective cohort</td><td align="center" valign="middle" rowspan="1" colspan="1">Prospective cohort</td><td align="center" valign="middle" rowspan="1" colspan="1">Prospective cohort</td><td align="center" colspan="2" valign="middle" rowspan="1">Retrospective cohort</td><td align="center" valign="middle" rowspan="1" colspan="1">Prospective cohort</td><td align="center" valign="middle" rowspan="1" colspan="1">Retrospective cohort</td></tr><tr style="background-color:#ECEFF7"><td align="center" style="border-left: thin solid; border-color: #000000;" valign="middle" rowspan="1" colspan="1">Author, Year</td><td align="center" valign="middle" rowspan="1" colspan="1">Haenisch et al.<sup>
<xref rid="B14" ref-type="bibr">14</xref>
</sup>, 2015</td><td align="center" valign="middle" rowspan="1" colspan="1">Gomm et al.<sup>
<xref rid="B15" ref-type="bibr">15</xref>
</sup>, 2016</td><td align="center" valign="middle" rowspan="1" colspan="1">Goldstein et al.<sup>
<xref rid="B35" ref-type="bibr">35</xref>
</sup>, 2017</td><td align="center" valign="middle" rowspan="1" colspan="1">Gray et al.<sup>
<xref rid="B28" ref-type="bibr">28</xref>
</sup>, 2017</td><td align="center" valign="middle" rowspan="1" colspan="1">Lochhead et al.<sup>
<xref rid="B27" ref-type="bibr">27</xref>
</sup>, 2017</td><td align="center" valign="middle" rowspan="1" colspan="1">Hwang et al.<sup>
<xref rid="B30" ref-type="bibr">30</xref>
</sup>, 2018</td><td align="center" colspan="2" valign="middle" rowspan="1">Park et al.<sup>
<xref rid="B31" ref-type="bibr">31</xref>
</sup>, 2018</td><td align="center" valign="middle" rowspan="1" colspan="1">Wod et al.<sup>
<xref rid="B29" ref-type="bibr">29</xref>
</sup>, 2018</td><td align="center" valign="middle" rowspan="1" colspan="1">Huang et al.<sup>
<xref rid="B37" ref-type="bibr">37</xref>
</sup>, 2019</td></tr><tr><td align="center" rowspan="8" style="background-color:#ECEFF7" valign="middle" colspan="1">Observational studies</td><td align="center" style="background-color:#126CA2; border-left: thin solid; border-color: #000000;" valign="middle" rowspan="1" colspan="1">LE</td><td align="center" style="background-color:#126CA2;" valign="middle" rowspan="1" colspan="1">II</td><td align="center" style="background-color:#126CA2;" valign="middle" rowspan="1" colspan="1">II</td><td align="center" style="background-color:#126CA2;" valign="middle" rowspan="1" colspan="1">II</td><td align="center" style="background-color:#126CA2;" valign="middle" rowspan="1" colspan="1">II</td><td align="center" style="background-color:#126CA2;" valign="middle" rowspan="1" colspan="1">II</td><td align="center" style="background-color:#126CA2;" valign="middle" rowspan="1" colspan="1">II</td><td align="center" style="background-color:#126CA2;" valign="middle" rowspan="1" colspan="1">II</td><td align="center" style="background-color:#126CA2;" valign="middle" rowspan="1" colspan="1">II</td><td align="center" style="background-color:#126CA2;" valign="middle" rowspan="1" colspan="1">II</td><td align="center" style="background-color:#126CA2;" valign="middle" rowspan="1" colspan="1">II</td></tr><tr style="background-color:#ECEFF7"><td align="center" style="border-left: thin solid; border-color: #000000;" valign="middle" rowspan="1" colspan="1">Conclusion</td><td align="center" valign="middle" rowspan="1" colspan="1">No association</td><td align="center" valign="middle" rowspan="1" colspan="1">Increased risk</td><td align="center" valign="middle" rowspan="1" colspan="1">Increased risk</td><td align="center" valign="middle" rowspan="1" colspan="1">Risk reduction</td><td align="center" valign="middle" rowspan="1" colspan="1">Increased risk</td><td align="center" valign="middle" rowspan="1" colspan="1">No association</td><td align="center" valign="middle" rowspan="1" colspan="1">No association</td><td align="center" valign="middle" rowspan="1" colspan="1">Risk reduction</td><td align="center" valign="middle" rowspan="1" colspan="1">No association</td><td align="center" valign="middle" rowspan="1" colspan="1">No association</td></tr><tr style="background-color:#ECEFF7"><td align="center" style="border-left: thin solid; border-color: #000000;" valign="middle" rowspan="1" colspan="1">Results</td><td align="center" valign="middle" rowspan="1" colspan="1">IRR=1.01;95%CI (0.96&#8211;1.06)</td><td align="center" valign="middle" rowspan="1" colspan="1">OR=1.55 (p&lt;0.001)</td><td align="center" valign="middle" rowspan="1" colspan="1">aHR=1.42;95%CI (1.07&#8211;1.84) Association between cumulative dose and risk of dementia with statistical significance (p-trend&lt;0.001)</td><td align="center" valign="middle" rowspan="1" colspan="1">HR=0.67, 95%CI (0.65&#8211;0.67)(p&lt;0.01)</td><td align="center" valign="middle" rowspan="1" colspan="1">AD: aOR=1.06;95%CI (0.93&#8211;1.21)nAD: aOR=1.20, 95%CI (1.05&#8211;1.37)(p=0.007). AD for high dose PPI: aOR=1.20; 95%CI (0.91&#8211;1.61)nAD for high dose PPI: aOR=0.95, 95%CI (0.74&#8211;1.22)</td><td align="center" valign="middle" rowspan="1" colspan="1">aHR=0.72;95%CI (0.51&#8211;1.03)</td><td align="center" valign="middle" rowspan="1" colspan="1">aOR=1,0; 95%CI (0,40&#8211;2,73)</td><td align="center" valign="middle" rowspan="1" colspan="1">OR=0.93, CI95% (0.90&#8211;0.97)(p=0.0008)</td><td align="center" valign="middle" rowspan="1" colspan="1">aOR=1.01;95%CI (0.97&#8211;1.06)</td><td align="center" valign="middle" rowspan="1" colspan="1">AD: aOR=0.88; 95%CI (0.80&#8211;0.97)VV: aOR=1.18, 95%CI (1.04&#8211;1.33)</td></tr><tr style="background-color:#ECEFF7"><td align="center" style="border-left: thin solid; border-color: #000000;" valign="middle" rowspan="1" colspan="1">Outcome</td><td align="center" valign="middle" rowspan="1" colspan="1">Dementia diagnosis</td><td align="center" valign="middle" rowspan="1" colspan="1">Dementia diagnosis or prescription of anti-dementia drugs</td><td align="center" valign="middle" rowspan="1" colspan="1">Dementia diagnosis</td><td align="center" valign="middle" rowspan="1" colspan="1">Dementia diagnosis</td><td align="center" valign="middle" rowspan="1" colspan="1">Diagnosis of Alzheimer's disease or non-Alzheimer dementia</td><td align="center" valign="middle" rowspan="1" colspan="1">Dementia diagnosis</td><td align="center" valign="middle" rowspan="1" colspan="1">Dementia diagnosis</td><td align="center" valign="middle" rowspan="1" colspan="1">Dementia diagnosis</td><td align="center" valign="middle" rowspan="1" colspan="1">Alzheimer's Disease Diagnosis</td><td align="center" valign="middle" rowspan="1" colspan="1">Development of Alzheimer's Disease or Vascular Dementia</td></tr><tr style="background-color:#ECEFF7"><td align="center" style="border-left: thin solid; border-color: #000000;" valign="middle" rowspan="1" colspan="1">Intervention</td><td align="center" valign="middle" rowspan="1" colspan="1">PPIs use</td><td align="center" valign="middle" rowspan="1" colspan="1">PPIs use</td><td align="center" valign="middle" rowspan="1" colspan="1">PPIs use (cumulative dose)</td><td align="center" valign="middle" rowspan="1" colspan="1">PPIs use</td><td align="center" valign="middle" rowspan="1" colspan="1">PPIs use</td><td align="center" valign="middle" rowspan="1" colspan="1">PPIs use (and H2 blockers)</td><td align="center" valign="middle" rowspan="1" colspan="1">Continuous PPIs&#8217; use</td><td align="center" valign="middle" rowspan="1" colspan="1">PPIs use</td><td align="center" valign="middle" rowspan="1" colspan="1">PPIs use (cumulative dose)</td><td align="center" valign="middle" rowspan="1" colspan="1">PPIs use</td></tr><tr style="background-color:#ECEFF7"><td align="center" style="border-left: thin solid; border-color: #000000;" valign="middle" rowspan="1" colspan="1">Sample</td><td align="center" valign="middle" rowspan="1" colspan="1">304,753</td><td align="center" valign="middle" rowspan="1" colspan="1">23,656</td><td align="center" valign="middle" rowspan="1" colspan="1">62,574</td><td align="center" valign="middle" rowspan="1" colspan="1">315,078</td><td align="center" valign="middle" rowspan="1" colspan="1">135,722</td><td align="center" valign="middle" rowspan="1" colspan="1">92,773</td><td align="center" valign="middle" rowspan="1" colspan="1">7,8 billion</td><td align="center" valign="middle" rowspan="1" colspan="1">23,912 (1:1)</td><td align="center" valign="middle" rowspan="1" colspan="1">353,576 (1:4)</td><td align="center" valign="middle" rowspan="1" colspan="1">41,029</td></tr><tr style="background-color:#ECEFF7"><td align="center" style="border-left: thin solid; border-color: #000000;" valign="middle" rowspan="1" colspan="1">Type of study</td><td align="center" valign="middle" rowspan="1" colspan="1">Retrospective cohort</td><td align="center" valign="middle" rowspan="1" colspan="1">Retrospective cohort</td><td align="center" valign="middle" rowspan="1" colspan="1">Retrospective cohort</td><td align="center" valign="middle" rowspan="1" colspan="1">Retrospective cohort</td><td align="center" valign="middle" rowspan="1" colspan="1">Retrospective cohort</td><td align="center" valign="middle" rowspan="1" colspan="1">Retrospective cohort</td><td align="center" valign="middle" rowspan="1" colspan="1">Cross-sectional</td><td align="center" valign="middle" rowspan="1" colspan="1">Case control</td><td align="center" valign="middle" rowspan="1" colspan="1">Case control</td><td align="center" valign="middle" rowspan="1" colspan="1">Case control</td></tr><tr style="background-color:#ECEFF7"><td align="center" style="border-left: thin solid; border-color: #000000;" valign="middle" rowspan="1" colspan="1">Author, Year</td><td align="center" valign="middle" rowspan="1" colspan="1">Park et al.<sup>
<xref rid="B36" ref-type="bibr">36</xref>
</sup>, 2019</td><td align="center" valign="middle" rowspan="1" colspan="1">Welu et al.<sup>
<xref rid="B32" ref-type="bibr">32</xref>
</sup>, 2019</td><td align="center" valign="middle" rowspan="1" colspan="1">Chen et al.<sup>
<xref rid="B33" ref-type="bibr">33</xref>
</sup>, 2020</td><td align="center" valign="middle" rowspan="1" colspan="1">Cooksey et al.<sup>
<xref rid="B34" ref-type="bibr">34</xref>
</sup>, 2020</td><td align="center" valign="middle" rowspan="1" colspan="1">Torres-Bondia et al.<sup>
<xref rid="B16" ref-type="bibr">16</xref>
</sup>, 2020</td><td align="center" valign="middle" rowspan="1" colspan="1">Wu et a.l<sup>
<xref rid="B38" ref-type="bibr">38</xref>
</sup>, 2020</td><td align="center" valign="middle" rowspan="1" colspan="1">Ma et al.<sup>
<xref rid="B42" ref-type="bibr">42</xref>
</sup>, 2020</td><td align="center" valign="middle" rowspan="1" colspan="1">Booker et al.<sup>
<xref rid="B41" ref-type="bibr">41</xref>
</sup>, 2016</td><td align="center" valign="middle" rowspan="1" colspan="1">Taipale et al.<sup>
<xref rid="B40" ref-type="bibr">40</xref>
</sup>, 2017</td><td align="center" valign="middle" rowspan="1" colspan="1">Imfeld et al.<sup>
<xref rid="B39" ref-type="bibr">39</xref>
</sup>, 2018</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>Abbreviations: LE: level of evidence; ACD: all-cause dementia; HR: hazard ratio; AD: Alzheimer's dementia; CI: confidence interval; p: p-value; MCI: Mild Cognitive Impairment; TSDDS: Total standardized daily doses; aSR: adjusted sequence ratio; PPI: Proton pump inhibitors; IRR: incidence rate ratio; aHR: adjusted hazard ratio; aOR; adjusted odds ratio; RR: relative risk; nAD: non-Alzheimer dementia.</p></fn></table-wrap-foot></table-wrap><p>For seven years, Gomm et al.<sup>
<xref rid="B15" ref-type="bibr">15</xref>
</sup> followed a cohort of individuals under regular use of PPIs with at least one prescription per quarter and also concluded the existence of this slight increase in risk (HR 1.44) compared with non-use.</p><p>The remaining prospective studies did not demonstrate the existence of this association, either in comparison with placebo or with H2-antagonists<sup>
<xref rid="B28" ref-type="bibr">28</xref>&#8211;<xref rid="B30" ref-type="bibr">30</xref>,<xref rid="B43" ref-type="bibr">43</xref>
</sup>.</p><p>In Denmark, Wod et al.<sup>
<xref rid="B29" ref-type="bibr">29</xref>
</sup> studied two cohorts of twins in different age groups (middle-aged and elderly), comparing PPI users and non-users, and had no statistically significant difference in cognitive decline between groups in both cohorts. When studying the effect of PPIs over the time of use<sup>
<xref rid="B28" ref-type="bibr">28</xref>
</sup> or adjusted for cumulative dose<sup>
<xref rid="B30" ref-type="bibr">30</xref>,<xref rid="B43" ref-type="bibr">43</xref>
</sup>, there was also no increase in the risk of developing dementia.</p><p>Regarding retrospective studies, four of them<sup>
<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B31" ref-type="bibr">31</xref>&#8211;<xref rid="B33" ref-type="bibr">33</xref>
</sup> found an association between the use of these drugs and cognitive decline. In Spain, Torres-Bondia et al.<sup>
<xref rid="B16" ref-type="bibr">16</xref>
</sup> found a slight increase in the risk of non-Alzheimer dementia compared with PPI non-users (adjusted odds ratio [aOR] 1.20), with no dose-dependent effect, which was not observed for Alzheimer's disease. In the United States of America (USA), Welu et al.<sup>
<xref rid="B32" ref-type="bibr">32</xref>
</sup> showed a 51% increase in the risk of developing dementia in a cohort of more than 23,000 war veterans with PPI consumption for more than 30 days compared to an equal number of veterans who had never been prescribed PPIs, although without correlation to the duration of the treatment or cumulative dose. A South Korean population cohort with about 1 million people was used for a study<sup>
<xref rid="B31" ref-type="bibr">31</xref>
</sup> that found an increased risk of developing dementia in PPI users (adjusted sequence ratio [aSR] of 1.21) after 3 years of use, which was more pronounced with omeprazole (aSR 1.24). In this study, different latency times of 1, 2, and 3 years were applied and the results showed that the relative risk decreased with the rise of latency time: adjusted incidence rate ratio (aIRR) of 1.13, 1.02, and 0.89, respectively; without application of latency time, the aIRR was 1.27. A study in Taiwan on people over 65 years of age, showed an increase in this risk (aHR 1.42; 95%CI 1.07&#8211;1.84), in a dose-dependent manner<sup>
<xref rid="B33" ref-type="bibr">33</xref>
</sup>. In contrast, two retrospective studies by Cooksey et al.<sup>
<xref rid="B34" ref-type="bibr">34</xref>
</sup>(in Scotland) and Goldstein et al.<sup>
<xref rid="B35" ref-type="bibr">35</xref>
</sup> (in the USA) showed a decrease of about 30% in the risk of dementia in PPI users (HR 0.67 and 0.78, respectively), either with regular or intermittent consumption of these drugs. Park et al.<sup>
<xref rid="B36" ref-type="bibr">36</xref>
</sup> evaluated the risk of dementia in PPI users compared to anti-H2 users, this time not verifying the harmful effect associated with the former, contradicting their own findings published in 2018. The remaining retrospective studies considered in this research did not show an increased risk, either in continuous or intermittent use<sup>
<xref rid="B37" ref-type="bibr">37</xref>
</sup> or in comparison with anti-H2<sup>
<xref rid="B38" ref-type="bibr">38</xref>
</sup>.</p></sec></sec><sec><title>Case control</title><p>The results of our search included three case-control studies. Imfeld et al. studied the development of Alzheimer's dementia (AD) and vascular dementia (VD) associated with prolonged PPI use in individuals over 65 years of age, and found no increased risk for either of these conditions compared with non-users (aOR 0.85 and 0.90, respectively), which remained the same when the analysis was done for each of the different PPIs or for their combined use<sup>
<xref rid="B39" ref-type="bibr">39</xref>
</sup>. Taipale et al. studied the development of Alzheimer's dementia associated with PPI use with 3-year lag window applied between exposure and outcome (aOR 1.03; 95%CI 1.00&#8211;1.05) compared with no use, with higher doses use (&#8805;1.5 defined daily doses per day; aOR 1.03; 95%CI 0.92&#8211;1.14) and with longer duration of use (&#8805;3 years of use; aOR 0.99; 95%CI 0.94&#8211;1.04), revealing no increased risk<sup>
<xref rid="B40" ref-type="bibr">40</xref>
</sup>. Another case-control study, carried out in Germany, which main outcome was the development of dementia dependent on predefined risk factors, concluded that there may be a modest protective effect of PPIs on the development of dementia (HR 0.93; 95%CI 0.90&#8211;0.97), along with statins and antihypertensives (<xref rid="t2" ref-type="table">Table 2</xref>)<sup>
<xref rid="B41" ref-type="bibr">41</xref>
</sup>.</p></sec><sec><title>Cross-sectional study</title><p>The only observational cross-sectional study obtained encompassed more than 7 billion surveys conducted in North American patients and did not demonstrate the existence of any association between PPI use and the development of dementia (<xref rid="t2" ref-type="table">Table 2</xref>)<sup>
<xref rid="B42" ref-type="bibr">42</xref>
</sup>.</p></sec><sec><title>Systematic reviews and meta-analyses</title><p>The search resulted in eight systematic reviews, seven of them comprising meta-analysis (<xref rid="t3" ref-type="table">Table 3</xref>)<sup>
<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B44" ref-type="bibr">44</xref>&#8211;<xref rid="B48" ref-type="bibr">48</xref>
</sup>. A systematic review published in 2017 included 11 studies with different methodologies and great heterogeneity, suggesting an increased risk of dementia with PPIs, but meta-analysis was not performed<sup>
<xref rid="B13" ref-type="bibr">13</xref>
</sup>. One of the identified meta-analyses encompassed six cohort studies and found a slightly increased risk of dementia as a result of PPI use, with a HR of 1.29, and 95%CI 1.12&#8211;1.49<sup>
<xref rid="B44" ref-type="bibr">44</xref>
</sup>.</p><table-wrap position="float" id="t3" orientation="portrait"><label>Table 3</label><caption><title>Systematic reviews.</title></caption><table frame="hsides" rules="rows"><colgroup width="14%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000"><tr style="background-color:#126CA2;"><th align="center" colspan="7" valign="middle" rowspan="1">Systematic reviews</th></tr><tr style="background-color:#126CA2;"><th align="left" valign="middle" rowspan="1" colspan="1">Author, Year</th><th align="center" valign="middle" rowspan="1" colspan="1">Type of study</th><th align="center" valign="middle" rowspan="1" colspan="1">Sample</th><th align="center" valign="middle" rowspan="1" colspan="1">Studies included</th><th align="center" valign="middle" rowspan="1" colspan="1">Results</th><th align="center" valign="middle" rowspan="1" colspan="1">Conclusion</th><th align="center" valign="middle" rowspan="1" colspan="1">LE</th></tr></thead><tbody style="border-bottom: thin solid; border-color: #000000"><tr style="background-color:#ECEFF7"><td align="left" valign="middle" rowspan="1" colspan="1">Batchelor et al.<sup>
<xref rid="B13" ref-type="bibr">13</xref>
</sup>, 2017</td><td align="center" valign="middle" rowspan="1" colspan="1">Systematic reviews</td><td align="center" valign="middle" rowspan="1" colspan="1">101,616</td><td align="center" valign="middle" rowspan="1" colspan="1">One experimental study and 10 observational studies (4 cohort, 1 case-control, 1 cross-sectional, 1 case series, and 3 case reports)</td><td align="center" valign="middle" rowspan="1" colspan="1">No meta-analysis</td><td align="center" valign="middle" rowspan="1" colspan="1">Increased risk</td><td align="center" valign="middle" rowspan="1" colspan="1">II</td></tr><tr style="background-color:#ECEFF7"><td align="left" valign="middle" rowspan="1" colspan="1">Hussain et al.<sup>
<xref rid="B17" ref-type="bibr">17</xref>
</sup>, 2020</td><td align="center" valign="middle" rowspan="1" colspan="1">Systematic review and meta-analysis</td><td align="center" valign="middle" rowspan="1" colspan="1">618,911</td><td align="center" valign="middle" rowspan="1" colspan="1">12 observational studies (8 cohort and 4 case-control)</td><td align="center" valign="middle" rowspan="1" colspan="1">RR=1.05, 95%CI 0.96&#8211;1.15</td><td align="center" valign="middle" rowspan="1" colspan="1">No association</td><td align="center" valign="middle" rowspan="1" colspan="1">I</td></tr><tr style="background-color:#ECEFF7"><td align="left" valign="middle" rowspan="1" colspan="1">Li et al.<sup>
<xref rid="B12" ref-type="bibr">12</xref>
</sup>, 2019</td><td align="center" valign="middle" rowspan="1" colspan="1">Systematic review and meta-analysis</td><td align="center" valign="middle" rowspan="1" colspan="1">106,599</td><td align="center" valign="middle" rowspan="1" colspan="1">6 cohort studies</td><td align="center" valign="middle" rowspan="1" colspan="1">RR=1.23; 95%CI 0.90&#8211;1.67Follow-up &lt; 5 years: RR=1.62, 95%CI 1.40&#8211;1.86 Follow-up &gt; 5years: RR=0.98, 95%CI 0.75&#8211;1.27</td><td align="center" valign="middle" rowspan="1" colspan="1">No association</td><td align="center" valign="middle" rowspan="1" colspan="1">I</td></tr><tr style="background-color:#ECEFF7"><td align="left" valign="middle" rowspan="1" colspan="1">Song et al.<sup>
<xref rid="B47" ref-type="bibr">47</xref>
</sup>, 2019</td><td align="center" valign="middle" rowspan="1" colspan="1">Systematic review and meta-analysis</td><td align="center" valign="middle" rowspan="1" colspan="1">642,305</td><td align="center" valign="middle" rowspan="1" colspan="1">10 observational studies (5 cohort, 4 case control, and 1 cross-sectional)</td><td align="center" valign="middle" rowspan="1" colspan="1">ACD: HR=1.04, 95%CI 0.92&#8211;1.15 AD: HR 0.96, 95%CI 0.83&#8211;1.09</td><td align="center" valign="middle" rowspan="1" colspan="1">No association</td><td align="center" valign="middle" rowspan="1" colspan="1">I</td></tr><tr style="background-color:#ECEFF7"><td align="left" valign="middle" rowspan="1" colspan="1">Zhang et al.<sup>
<xref rid="B44" ref-type="bibr">44</xref>
</sup>, 2020</td><td align="center" valign="middle" rowspan="1" colspan="1">Systematic review and meta-analysis</td><td align="center" valign="middle" rowspan="1" colspan="1">166,146</td><td align="center" valign="middle" rowspan="1" colspan="1">6 cohort studies</td><td align="center" valign="middle" rowspan="1" colspan="1">HR=1.29, 95%CI 1.12&#8211;1.49</td><td align="center" valign="middle" rowspan="1" colspan="1">Increased risk</td><td align="center" valign="middle" rowspan="1" colspan="1">I</td></tr><tr style="background-color:#ECEFF7"><td align="left" valign="middle" rowspan="1" colspan="1">Desai et al.<sup>
<xref rid="B46" ref-type="bibr">46</xref>
</sup>, 2020</td><td align="center" valign="middle" rowspan="1" colspan="1">Systematic review and meta-analysis</td><td align="center" valign="middle" rowspan="1" colspan="1">308,249</td><td align="center" valign="middle" rowspan="1" colspan="1">One experimental study and 5 prospective observational</td><td align="center" valign="middle" rowspan="1" colspan="1">ACD: HR=1.16, 95%CI 0.86&#8211;1.47</td><td align="center" valign="middle" rowspan="1" colspan="1">No association</td><td align="center" valign="middle" rowspan="1" colspan="1">I</td></tr><tr style="background-color:#ECEFF7"><td align="left" valign="middle" rowspan="1" colspan="1">Khan et al.<sup>
<xref rid="B45" ref-type="bibr">45</xref>
</sup>, 2020</td><td align="center" valign="middle" rowspan="1" colspan="1">Systematic review and meta-analysis</td><td align="center" valign="middle" rowspan="1" colspan="1">642,949</td><td align="center" valign="middle" rowspan="1" colspan="1">11 observational studies (6 cohort, 4 case control, and 1 cross-sectional)</td><td align="center" valign="middle" rowspan="1" colspan="1">ACD: HR=1.10; OR=1.03.AD: HR=1.06; OR=0.96</td><td align="center" valign="middle" rowspan="1" colspan="1">No association</td><td align="center" valign="middle" rowspan="1" colspan="1">I</td></tr><tr style="background-color:#ECEFF7"><td align="left" valign="middle" rowspan="1" colspan="1">Zhang et al.<sup>
<xref rid="B48" ref-type="bibr">48</xref>
</sup>, 2020</td><td align="center" valign="middle" rowspan="1" colspan="1">Systematic review and meta-analysis</td><td align="center" valign="middle" rowspan="1" colspan="1">371,951</td><td align="center" valign="middle" rowspan="1" colspan="1">10 observational studies</td><td align="center" valign="middle" rowspan="1" colspan="1">OR=0.87; 95%CI 0.62&#8211;1.22</td><td align="center" valign="middle" rowspan="1" colspan="1">No association</td><td align="center" valign="middle" rowspan="1" colspan="1">II</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>Abbreviations: RR: relative risk; CI: confidence interval; ACD: all-cause dementia; AD: Alzheimer's dementia; HR: hazard ratio; OR: odds ratio.</p></fn></table-wrap-foot></table-wrap><p>There is some overlap of studies included in meta-analyses, notably all cohorts included in Zhang's et al.<sup>
<xref rid="B44" ref-type="bibr">44</xref>
</sup> meta-analysis are covered by Khan et al.<sup>
<xref rid="B45" ref-type="bibr">45</xref>
</sup> meta-analysis.</p><p>None of the six remaining meta-analyses in review excluded in this research presented evidence to support the association between PPIs and dementia<sup>
<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B45" ref-type="bibr">45</xref>&#8211;<xref rid="B48" ref-type="bibr">48</xref>
</sup>. Among the most recent ones, the review by Khan et al.<sup>
<xref rid="B45" ref-type="bibr">45</xref>
</sup>, which included 11 observational studies with 642,949 individuals, found a HR for dementia from all-causes of 1.11 and 95%CI 0.88&#8211;1.37, and for Alzheimer's disease a 95%CI 0.72&#8211;1.55.</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Overall, this evidence-based review identified nine studies classified as level of evidence I (five meta-analyses, three observational studies, and one randomized clinical trial) and eight studies classified as level of evidence II (one systematic review, four longitudinal observational, one cross-sectional, and two case-control studies) that found no statistically significant evidence of a relationship between PPI use and the development of dementia. Three level of evidence I studies (one meta-analysis and two longitudinal observational studies) found an association between PPI use and dementia. In the study by Haenisch et al.<sup>
<xref rid="B14" ref-type="bibr">14</xref>
</sup>, information about the pattern of drug use was not consistently available. In the meta-analysis by Zhang et al.<sup>
<xref rid="B44" ref-type="bibr">44</xref>
</sup>, only cohort studies were included and there was substantial heterogeneity between studies; different indicators (OR and HR) were included as measures of similar effect, which constitutes a bias. In these studies, the most expressive measure of effect was a HR of 1.44, 95%CI 1.36&#8211;1.52 (p-value[p]&lt;0 .001) which was obtained in a prospective cohort study in a population aged 75 years and over<sup>
<xref rid="B15" ref-type="bibr">15</xref>
</sup>. Five studies with level of evidence II found an increased risk (one systematic review without meta-analysis and four longitudinal observational studies), where the highest risk measure was an OR of 1.55<sup>
<xref rid="B32" ref-type="bibr">32</xref>
</sup>. The study by Batchelor et al.<sup>
<xref rid="B13" ref-type="bibr">13</xref>
</sup> had several limitations, namely data heterogeneity, variability in study designs, and clinical diversity, with an important risk of bias.</p><p>The study by Park et al.<sup>
<xref rid="B36" ref-type="bibr">36</xref>
</sup> highlighted the importance of applying a window time after the start of PPIs, during which cases of dementia may arise in patients without a previous diagnosis, although without an etiological relationship with the drug, thus reducing the protopathic bias. The decrease in IRR with increasing time window weakens the evidence for the association between PPI use and dementia. In three studies with level of evidence II<sup>
<xref rid="B36" ref-type="bibr">36</xref>,<xref rid="B37" ref-type="bibr">37</xref>,<xref rid="B41" ref-type="bibr">41</xref>
</sup> there was a decrease in the risk of developing dementia, with the lowest HR recorded 0.67, 95%CI 0.65&#8211;0.67 (p&lt;0.01) and resulting from a retrospective cohort study, where it was not possible to assess the duration of use or dosage of PPI<sup>
<xref rid="B34" ref-type="bibr">34</xref>
</sup>.</p><p>Regarding the strengths of this review, the expressive sample size of the included studies stands out, comprising data from different countries and continents. The selected outcome included cognitive impairment and dementia of all etiologies, not limited to Alzheimer's disease. Only level of evidence I and II studies were included, with most of the more robust ones were classified as level I.</p><p>As the main limitation, we highlight the great heterogeneity among the results, which are somewhat contradicting. Only one experimental study was identified, with a predominance of observational studies. Other limitations are the lack of methodological consistency of the intervention (dose, duration, pattern of intake, confirmation of treatment adherence) and the outcome (clinical diagnosis, neuropsychological tests, prescription of antidementia drugs), and the fact that it was not considered a window time in most studies. Additional research is needed because there is biological evidence that PPIs could affect the brain and increase the risk of dementia and AD.</p><p>In conclusion, although the available evidence is discordant, most level of evidence I studies have not found a statistically significant association between PPI use and the development of dementia or cognitive impairment. Therefore, we believe further studies on this topic are needed, particularly randomized clinical trials.</p></sec></body><back><fn-group><fn fn-type="other" id="fn1"><p>This study was conducted by a Group of doctors from the Group of Health Centers of West Lisbon and Oeiras, Oeiras, Portugal.</p></fn><fn fn-type="supported-by" id="fn2"><p>
<bold>Funding:</bold> none.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katz</surname><given-names>PO</given-names></name><name name-style="western"><surname>Gerson</surname><given-names>LB</given-names></name><name name-style="western"><surname>Vela</surname><given-names>MF</given-names></name></person-group><article-title>Guidelines for the diagnosis and management of gastroesophageal reflux disease</article-title><source>Am J Gastroenterol</source><year>2013</year><volume>108</volume><issue>3</issue><fpage>308</fpage><lpage>328</lpage><comment>quiz 29. </comment><pub-id pub-id-type="doi">10.1038/ajg.2012.444</pub-id><pub-id pub-id-type="pmid">23419381</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qato</surname><given-names>DM</given-names></name><name name-style="western"><surname>Wilder</surname><given-names>J</given-names></name><name name-style="western"><surname>Schumm</surname><given-names>LP</given-names></name><name name-style="western"><surname>Gillet</surname><given-names>V</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>GC</given-names></name></person-group><article-title>Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011</article-title><source>JAMA Intern Med</source><year>2016</year><volume>176</volume><issue>4</issue><fpage>473</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2015.8581</pub-id><pub-id pub-id-type="pmid">26998708</pub-id><pub-id pub-id-type="pmcid">PMC5024734</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Batuwitage</surname><given-names>BT</given-names></name><name name-style="western"><surname>Kingham</surname><given-names>JGC</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>NE</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>RL</given-names></name></person-group><article-title>Inappropriate prescribing of proton pump inhibitors in primary care</article-title><source>Postgrad Med J</source><year>2007</year><volume>83</volume><issue>975</issue><fpage>66</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1136/pgmj.2006.051151</pub-id><pub-id pub-id-type="pmid">17267683</pub-id><pub-id pub-id-type="pmcid">PMC2599965</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matuz</surname><given-names>M</given-names></name><name name-style="western"><surname>Benk&#337;</surname><given-names>R</given-names></name><name name-style="western"><surname>Engi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Schv&#225;b</surname><given-names>K</given-names></name><name name-style="western"><surname>Dor&#243;</surname><given-names>P</given-names></name><name name-style="western"><surname>Viola</surname><given-names>R</given-names></name><etal/></person-group><article-title>Use of proton pump inhibitors in hungary: mixed-method study to reveal scale and characteristics</article-title><source>Front Pharmacol</source><year>2020</year><volume>11</volume><fpage>552102</fpage><lpage>552102</lpage><pub-id pub-id-type="doi">10.3389/fphar.2020.552102</pub-id><pub-id pub-id-type="pmid">33013389</pub-id><pub-id pub-id-type="pmcid">PMC7506043</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Savarino</surname><given-names>V</given-names></name><name name-style="western"><surname>Marabotto</surname><given-names>E</given-names></name><name name-style="western"><surname>Zentilin</surname><given-names>P</given-names></name><name name-style="western"><surname>Furnari</surname><given-names>M</given-names></name><name name-style="western"><surname>Bodini</surname><given-names>G</given-names></name><name name-style="western"><surname>Maria</surname><given-names>C</given-names></name><etal/></person-group><article-title>The appropriate use of proton-pump inhibitors</article-title><source>Minerva Med</source><year>2018</year><volume>109</volume><issue>5</issue><fpage>386</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.23736/S0026-4806.18.05705-1</pub-id><pub-id pub-id-type="pmid">29856192</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaynes</surname><given-names>M</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>AB</given-names></name></person-group><article-title>The risks of long-term use of proton pump inhibitors: a critical review</article-title><source>Ther Adv Drug Saf</source><year>2018</year><volume>10</volume><fpage>2042098618809927</fpage><lpage>2042098618809927</lpage><pub-id pub-id-type="doi">10.1177/2042098618809927</pub-id><pub-id pub-id-type="pmid">31019676</pub-id><pub-id pub-id-type="pmcid">PMC6463334</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>YX</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>JD</given-names></name><name name-style="western"><surname>Epstein</surname><given-names>S</given-names></name><name name-style="western"><surname>Metz</surname><given-names>DC</given-names></name></person-group><article-title>Long-term proton pump inhibitor therapy and risk of hip fracture</article-title><source>JAMA</source><year>2006</year><volume>296</volume><issue>24</issue><fpage>2947</fpage><lpage>2953</lpage><pub-id pub-id-type="doi">10.1001/jama.296.24.2947</pub-id><pub-id pub-id-type="pmid">17190895</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lambert</surname><given-names>AA</given-names></name><name name-style="western"><surname>Lam</surname><given-names>JO</given-names></name><name name-style="western"><surname>Paik</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Ugarte-Gil</surname><given-names>C</given-names></name><name name-style="western"><surname>Drummond</surname><given-names>MB</given-names></name><name name-style="western"><surname>Crowell</surname><given-names>TA</given-names></name></person-group><article-title>Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><issue>6</issue><elocation-id>e0128004</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0128004</pub-id><pub-id pub-id-type="pmid">26042842</pub-id><pub-id pub-id-type="pmcid">PMC4456166</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poly</surname><given-names>TN</given-names></name><name name-style="western"><surname>Islam</surname><given-names>MM</given-names></name><name name-style="western"><surname>Yang</surname><given-names>HC</given-names></name><name name-style="western"><surname>Wu</surname><given-names>CC</given-names></name><name name-style="western"><surname>Li</surname><given-names>YCJ</given-names></name></person-group><article-title>Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies</article-title><source>Osteoporos Int</source><year>2019</year><volume>30</volume><issue>1</issue><fpage>103</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1007/s00198-018-4788-y</pub-id><pub-id pub-id-type="pmid">30539272</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>American Geriatrics Society Beers Criteria<sup>&#174;</sup> Update Expert Panel</collab></person-group><part-title>American Geriatrics Society 2019 Updated AGS Beers Criteria<sup>&#174;</sup> for potentially inappropriate medication use in older adults</part-title><source>J Am Geriatr Soc</source><year>2019</year><volume>67</volume><issue>4</issue><fpage>674</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1111/jgs.15767</pub-id><pub-id pub-id-type="pmid">30693946</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fallahzadeh</surname><given-names>MK</given-names></name><name name-style="western"><surname>Haghighi</surname><given-names>AB</given-names></name><name name-style="western"><surname>Namazi</surname><given-names>MR</given-names></name></person-group><article-title>Proton pump inhibitors: predisposers to Alzheimer disease?</article-title><source>J Clin Pharm Ther</source><year>2010</year><volume>35</volume><issue>2</issue><fpage>125</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2710.2009.01100.x</pub-id><pub-id pub-id-type="pmid">20456731</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Z</given-names></name></person-group><article-title>Proton pump inhibitor use and risk of dementia: systematic review and meta-analysis</article-title><source>Medicine (Baltimore)</source><year>2019</year><volume>98</volume><issue>7</issue><elocation-id>e14422</elocation-id><pub-id pub-id-type="doi">10.1097/MD.0000000000014422</pub-id><pub-id pub-id-type="pmid">30762748</pub-id><pub-id pub-id-type="pmcid">PMC6408083</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Batchelor</surname><given-names>R</given-names></name><name name-style="western"><surname>Gilmartin</surname><given-names>JFM</given-names></name><name name-style="western"><surname>Kemp</surname><given-names>W</given-names></name><name name-style="western"><surname>Hopper</surname><given-names>I</given-names></name><name name-style="western"><surname>Liew</surname><given-names>D</given-names></name></person-group><article-title>Dementia, cognitive impairment and proton pump inhibitor therapy: a systematic review</article-title><source>J Gastroenterol Hepatol</source><year>2017</year><volume>32</volume><issue>8</issue><fpage>1426</fpage><lpage>1435</lpage><pub-id pub-id-type="doi">10.1111/jgh.13750</pub-id><pub-id pub-id-type="pmid">28128476</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haenisch</surname><given-names>B</given-names></name><name name-style="western"><surname>von Holt</surname><given-names>K</given-names></name><name name-style="western"><surname>Wiese</surname><given-names>B</given-names></name><name name-style="western"><surname>Prokein</surname><given-names>J</given-names></name><name name-style="western"><surname>Lange</surname><given-names>C</given-names></name><name name-style="western"><surname>Ernst</surname><given-names>A</given-names></name><etal/></person-group><article-title>Risk of dementia in elderly patients with the use of proton pump inhibitors</article-title><source>Eur Arch Psychiatry Clin Neurosci</source><year>2015</year><volume>265</volume><issue>5</issue><fpage>419</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1007/s00406-014-0554-0</pub-id><pub-id pub-id-type="pmid">25341874</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomm</surname><given-names>W</given-names></name><name name-style="western"><surname>von Holt</surname><given-names>K</given-names></name><name name-style="western"><surname>Thom&#233;</surname><given-names>F</given-names></name><name name-style="western"><surname>Broich</surname><given-names>K</given-names></name><name name-style="western"><surname>Maier</surname><given-names>W</given-names></name><name name-style="western"><surname>Fink</surname><given-names>A</given-names></name><etal/></person-group><article-title>Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis</article-title><source>JAMA Neurol</source><year>2016</year><volume>73</volume><issue>4</issue><fpage>410</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2015.4791</pub-id><pub-id pub-id-type="pmid">26882076</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torres-Bondia</surname><given-names>F</given-names></name><name name-style="western"><surname>Dakterzada</surname><given-names>F</given-names></name><name name-style="western"><surname>Galv&#225;n</surname><given-names>L</given-names></name><name name-style="western"><surname>Buti</surname><given-names>M</given-names></name><name name-style="western"><surname>Besanson</surname><given-names>G</given-names></name><name name-style="western"><surname>Gill</surname><given-names>E</given-names></name><etal/></person-group><article-title>Proton pump inhibitors and the risk of Alzheimer's disease and non-Alzheimer's dementias</article-title><source>Sci Rep</source><year>2020</year><volume>10</volume><issue>1</issue><fpage>21046</fpage><lpage>21046</lpage><pub-id pub-id-type="doi">10.1038/s41598-020-78199-0</pub-id><pub-id pub-id-type="pmid">33273636</pub-id><pub-id pub-id-type="pmcid">PMC7713356</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hussain</surname><given-names>S</given-names></name><name name-style="western"><surname>Singh</surname><given-names>A</given-names></name><name name-style="western"><surname>Zameer</surname><given-names>S</given-names></name><name name-style="western"><surname>Jamali</surname><given-names>MC</given-names></name><name name-style="western"><surname>Baxi</surname><given-names>H</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>SO</given-names></name><etal/></person-group><article-title>No association between proton pump inhibitors use and risk of dementia: evidence from a meta-analysis</article-title><source>J Gastroenterol Hepatol</source><year>2020</year><volume>35</volume><issue>1</issue><fpage>19</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1111/jgh.14789</pub-id><pub-id pub-id-type="pmid">31334885</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vogiatzoglou</surname><given-names>A</given-names></name><name name-style="western"><surname>Smith</surname><given-names>AD</given-names></name><name name-style="western"><surname>Nurk</surname><given-names>E</given-names></name><name name-style="western"><surname>Drevon</surname><given-names>CA</given-names></name><name name-style="western"><surname>Ueland</surname><given-names>PM</given-names></name><name name-style="western"><surname>Vollset</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Cognitive function in an elderly population: interaction between vitamin B12 status, depression, and apolipoprotein E &#949;4: the Hordaland Homocysteine Study</article-title><source>Psychosom Med</source><year>2013</year><volume>75</volume><issue>1</issue><fpage>20</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1097/PSY.0b013e3182761b6c</pub-id><pub-id pub-id-type="pmid">23213264</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O'Leary</surname><given-names>F</given-names></name><name name-style="western"><surname>Allman-Farinelli</surname><given-names>M</given-names></name><name name-style="western"><surname>Samman</surname><given-names>S</given-names></name></person-group><article-title>Vitamin B<sup>12</sup> status, cognitive decline and dementia: a systematic review of prospective cohort studies</article-title><source>Br J Nutr</source><year>2012</year><volume>108</volume><issue>11</issue><fpage>1948</fpage><lpage>1961</lpage><pub-id pub-id-type="doi">10.1017/S0007114512004175</pub-id><pub-id pub-id-type="pmid">23084026</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reynolds</surname><given-names>E</given-names></name></person-group><article-title>Vitamin B<sup>12</sup>, folic acid, and the nervous system</article-title><source>Lancet Neurol</source><year>2006</year><volume>5</volume><issue>11</issue><fpage>949</fpage><lpage>960</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(06)70598-1</pub-id><pub-id pub-id-type="pmid">17052662</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>FC</given-names></name><name name-style="western"><surname>Ho</surname><given-names>YF</given-names></name><name name-style="western"><surname>Hung</surname><given-names>LC</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CF</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>TH</given-names></name></person-group><article-title>Determination and pharmacokinetic profile of omeprazole in rat blood, brain and bile by microdialysis and high-performance liquid chromatography</article-title><source>J Chromatogr A</source><year>2002</year><volume>949</volume><issue>1-2</issue><fpage>35</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/s0021-9673(01)01225-0</pub-id><pub-id pub-id-type="pmid">11999751</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rojo</surname><given-names>LE</given-names></name><name name-style="western"><surname>Alzate-Morales</surname><given-names>J</given-names></name><name name-style="western"><surname>Saavedra</surname><given-names>IN</given-names></name><name name-style="western"><surname>Davies</surname><given-names>P</given-names></name><name name-style="western"><surname>Maccioni</surname><given-names>RB</given-names></name></person-group><article-title>Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease</article-title><source>J Alzheimers Dis</source><year>2010</year><volume>19</volume><issue>2</issue><fpage>573</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.3233/JAD-2010-1262</pub-id><pub-id pub-id-type="pmid">20110603</pub-id><pub-id pub-id-type="pmcid">PMC2951486</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Badiola</surname><given-names>N</given-names></name><name name-style="western"><surname>Alcalde</surname><given-names>V</given-names></name><name name-style="western"><surname>Pujol</surname><given-names>A</given-names></name><name name-style="western"><surname>M&#252;nter</surname><given-names>LM</given-names></name><name name-style="western"><surname>Multhaup</surname><given-names>G</given-names></name><name name-style="western"><surname>Lle&#243;</surname><given-names>A</given-names></name><etal/></person-group><article-title>The proton-pump inhibitor lansoprazole enhances amyloid beta production</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>3</issue><elocation-id>e58837</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0058837</pub-id><pub-id pub-id-type="pmid">23520537</pub-id><pub-id pub-id-type="pmcid">PMC3592824</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Majumdar</surname><given-names>A</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>D</given-names></name><name name-style="western"><surname>Asamoah</surname><given-names>N</given-names></name><name name-style="western"><surname>Buxbaum</surname><given-names>A</given-names></name><name name-style="western"><surname>Sohar</surname><given-names>I</given-names></name><name name-style="western"><surname>Lobel</surname><given-names>P</given-names></name><etal/></person-group><article-title>Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils</article-title><source>Mol Biol Cell</source><year>2007</year><volume>18</volume><issue>4</issue><fpage>1490</fpage><lpage>1496</lpage><pub-id pub-id-type="doi">10.1091/mbc.e06-10-0975</pub-id><pub-id pub-id-type="pmid">17314396</pub-id><pub-id pub-id-type="pmcid">PMC1838985</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pillay</surname><given-names>CS</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>E</given-names></name><name name-style="western"><surname>Dennison</surname><given-names>C</given-names></name></person-group><article-title>Endolysosomal proteolysis and its regulation</article-title><source>Biochem J</source><year>2002</year><volume>363</volume><issue>Pt 3</issue><fpage>417</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1042/0264-6021:3630417</pub-id><pub-id pub-id-type="pmid">11964142</pub-id><pub-id pub-id-type="pmcid">PMC1222494</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mattsson</surname><given-names>JP</given-names></name><name name-style="western"><surname>V&#228;&#228;n&#228;nen</surname><given-names>K</given-names></name><name name-style="western"><surname>Wallmark</surname><given-names>B</given-names></name><name name-style="western"><surname>Lorentzon</surname><given-names>P</given-names></name></person-group><article-title>Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases</article-title><source>Biochim Biophys Acta</source><year>1991</year><volume>1065</volume><issue>2</issue><fpage>261</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1016/0005-2736(91)90238-4</pub-id><pub-id pub-id-type="pmid">1647821</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moayyedi</surname><given-names>P</given-names></name><name name-style="western"><surname>Eikelboom</surname><given-names>JW</given-names></name><name name-style="western"><surname>Bosch</surname><given-names>J</given-names></name><name name-style="western"><surname>Connolly</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Dyal</surname><given-names>L</given-names></name><name name-style="western"><surname>Shestakovska</surname><given-names>O</given-names></name><etal/></person-group><article-title>Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin</article-title><source>Gastroenterology</source><year>2019</year><volume>157</volume><issue>3</issue><fpage>682.e2</fpage><lpage>691.e2</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2019.05.056</pub-id><pub-id pub-id-type="pmid">31152740</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lochhead</surname><given-names>P</given-names></name><name name-style="western"><surname>Hagan</surname><given-names>K</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>AD</given-names></name><name name-style="western"><surname>Khalili</surname><given-names>H</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>LH</given-names></name><name name-style="western"><surname>Grodstein</surname><given-names>F</given-names></name><etal/></person-group><article-title>Association between proton pump inhibitor use and cognitive function in women</article-title><source>Gastroenterology</source><year>2017</year><volume>153</volume><issue>4</issue><fpage>971.e4</fpage><lpage>979.e4</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2017.06.061</pub-id><pub-id pub-id-type="pmid">28728964</pub-id><pub-id pub-id-type="pmcid">PMC5623145</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wod</surname><given-names>M</given-names></name><name name-style="western"><surname>Hallas</surname><given-names>J</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>K</given-names></name><name name-style="western"><surname>Rodr&#237;guez</surname><given-names>LAG</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>K</given-names></name><name name-style="western"><surname>Gaist</surname><given-names>D</given-names></name></person-group><article-title>Lack of association between proton pump inhibitor use and cognitive decline</article-title><source>Clin Gastroenterol Hepatol</source><year>2018</year><volume>16</volume><issue>5</issue><fpage>681</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2018.01.034</pub-id><pub-id pub-id-type="pmid">29391266</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hwang</surname><given-names>IC</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J</given-names></name><name name-style="western"><surname>Park</surname><given-names>SM</given-names></name></person-group><article-title>A nationwide population-based cohort study of dementia risk among acid suppressant users</article-title><source>Am J Geriatr Psychiatry</source><year>2018</year><volume>26</volume><issue>11</issue><fpage>1175</fpage><lpage>1183</lpage><pub-id pub-id-type="doi">10.1016/j.jagp.2018.06.002</pub-id><pub-id pub-id-type="pmid">30072307</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>SK</given-names></name><name name-style="western"><surname>Baek</surname><given-names>YH</given-names></name><name name-style="western"><surname>Pratt</surname><given-names>N</given-names></name><name name-style="western"><surname>Ellett</surname><given-names>LL</given-names></name><name name-style="western"><surname>Shin</surname><given-names>JY</given-names></name></person-group><article-title>The uncertainty of the association between proton pump inhibitor use and the risk of dementia: prescription sequence symmetry analysis using a Korean healthcare database between 2002 and 2013</article-title><source>Drug Saf</source><year>2018</year><volume>41</volume><issue>6</issue><fpage>615</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1007/s40264-018-0638-2</pub-id><pub-id pub-id-type="pmid">29397553</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Welu</surname><given-names>J</given-names></name><name name-style="western"><surname>Metzger</surname><given-names>J</given-names></name><name name-style="western"><surname>Bebensee</surname><given-names>S</given-names></name><name name-style="western"><surname>Ahrendt</surname><given-names>A</given-names></name><name name-style="western"><surname>Vasek</surname><given-names>M</given-names></name></person-group><article-title>Proton pump inhibitor use and risk of dementia in the veteran population</article-title><source>Fed Pract</source><year>2019</year><volume>36</volume><issue>Suppl 4</issue><fpage>S27</fpage><lpage>S31</lpage><pub-id pub-id-type="pmid">31296980</pub-id><pub-id pub-id-type="pmcid">PMC6604981</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>LY</given-names></name><name name-style="western"><surname>Lin</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Wu</surname><given-names>WT</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YC</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CL</given-names></name><name name-style="western"><surname>Kao</surname><given-names>J</given-names></name><etal/></person-group><article-title>Clinical use of acid suppressants and risk of dementia in the elderly: a pharmaco-epidemiological cohort study</article-title><source>Int J Environ Res Public Health</source><year>2020</year><volume>17</volume><issue>21</issue><fpage>8271</fpage><lpage>8271</lpage><pub-id pub-id-type="doi">10.3390/ijerph17218271</pub-id><pub-id pub-id-type="pmid">33182362</pub-id><pub-id pub-id-type="pmcid">PMC7664895</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cooksey</surname><given-names>R</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>J</given-names></name><name name-style="western"><surname>Dennis</surname><given-names>MS</given-names></name><name name-style="western"><surname>Escott-Price</surname><given-names>V</given-names></name><name name-style="western"><surname>Lyons</surname><given-names>RA</given-names></name><name name-style="western"><surname>Seaborne</surname><given-names>M</given-names></name><etal/></person-group><article-title>Proton pump inhibitors and dementia risk: evidence from a cohort study using linked routinely collected national health data in Wales, UK</article-title><source>PLoS One</source><year>2020</year><volume>15</volume><issue>9</issue><elocation-id>e0237676</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0237676</pub-id><pub-id pub-id-type="pmid">32946449</pub-id><pub-id pub-id-type="pmcid">PMC7500586</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldstein</surname><given-names>FC</given-names></name><name name-style="western"><surname>Steenland</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><name name-style="western"><surname>Wharton</surname><given-names>W</given-names></name><name name-style="western"><surname>Levey</surname><given-names>AI</given-names></name><name name-style="western"><surname>Hajjar</surname><given-names>I</given-names></name></person-group><article-title>Proton pump inhibitors and risk of mild cognitive impairment and dementia</article-title><source>J Am Geriatr Soc</source><year>2017</year><volume>65</volume><issue>9</issue><fpage>1969</fpage><lpage>1974</lpage><pub-id pub-id-type="doi">10.1111/jgs.14956</pub-id><pub-id pub-id-type="pmid">28590010</pub-id><pub-id pub-id-type="pmcid">PMC5797939</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>SK</given-names></name><name name-style="western"><surname>Nam</surname><given-names>JH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H</given-names></name><name name-style="western"><surname>Chung</surname><given-names>H</given-names></name><name name-style="western"><surname>Lee</surname><given-names>EK</given-names></name><name name-style="western"><surname>Shin</surname><given-names>JY</given-names></name></person-group><article-title>Beyond uncertainty: negative findings for the association between the use of proton pump inhibitors and risk of dementia</article-title><source>J Gastroenterol Hepatol</source><year>2019</year><volume>34</volume><issue>12</issue><fpage>2135</fpage><lpage>2143</lpage><pub-id pub-id-type="doi">10.1111/jgh.14745</pub-id><pub-id pub-id-type="pmid">31145825</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>ST</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>LY</given-names></name><name name-style="western"><surname>Chen</surname><given-names>LK</given-names></name><name name-style="western"><surname>Peng</surname><given-names>LN</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>FY</given-names></name></person-group><article-title>Does long-term proton pump inhibitor use increase risk of dementia? Not really! Results of the group-based trajectory analysis</article-title><source>Clin Pharmacol Ther</source><year>2019</year><volume>106</volume><issue>3</issue><fpage>616</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1002/cpt.1430</pub-id><pub-id pub-id-type="pmid">30861103</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>CL</given-names></name><name name-style="western"><surname>Lei</surname><given-names>WY</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JS</given-names></name><name name-style="western"><surname>Lin</surname><given-names>CE</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CL</given-names></name><name name-style="western"><surname>Wen</surname><given-names>SH</given-names></name></person-group><article-title>Acid suppressants use and the risk of dementia: a population-based propensity score-matched cohort study</article-title><source>PLoS One</source><year>2020</year><volume>15</volume><issue>11</issue><elocation-id>e0242975</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0242975</pub-id><pub-id pub-id-type="pmid">33253311</pub-id><pub-id pub-id-type="pmcid">PMC7703973</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imfeld</surname><given-names>P</given-names></name><name name-style="western"><surname>Bodmer</surname><given-names>M</given-names></name><name name-style="western"><surname>Jick</surname><given-names>SS</given-names></name><name name-style="western"><surname>Meier</surname><given-names>CR</given-names></name></person-group><article-title>Proton pump inhibitor use and risk of developing Alzheimer's disease or vascular dementia: a case-control analysis</article-title><source>Drug Saf</source><year>2018</year><volume>41</volume><issue>12</issue><fpage>1387</fpage><lpage>1396</lpage><pub-id pub-id-type="doi">10.1007/s40264-018-0704-9</pub-id><pub-id pub-id-type="pmid">30146658</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taipale</surname><given-names>H</given-names></name><name name-style="western"><surname>Tolppanen</surname><given-names>AM</given-names></name><name name-style="western"><surname>Tiihonen</surname><given-names>M</given-names></name><name name-style="western"><surname>Tanskanen</surname><given-names>A</given-names></name><name name-style="western"><surname>Tiihonen</surname><given-names>J</given-names></name><name name-style="western"><surname>Hartikainen</surname><given-names>S</given-names></name></person-group><article-title>No association between proton pump inhibitor use and risk of Alzheimer's disease</article-title><source>Am J Gastroenterol</source><year>2017</year><volume>112</volume><issue>12</issue><fpage>1802</fpage><lpage>1808</lpage><pub-id pub-id-type="doi">10.1038/ajg.2017.196</pub-id><pub-id pub-id-type="pmid">28695906</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Booker</surname><given-names>A</given-names></name><name name-style="western"><surname>Jacob</surname><given-names>LE</given-names></name><name name-style="western"><surname>Rapp</surname><given-names>M</given-names></name><name name-style="western"><surname>Bohlken</surname><given-names>J</given-names></name><name name-style="western"><surname>Kostev</surname><given-names>K</given-names></name></person-group><article-title>Risk factors for dementia diagnosis in German primary care practices</article-title><source>Int Psychogeriatr</source><year>2016</year><volume>28</volume><issue>7</issue><fpage>1059</fpage><lpage>1065</lpage><pub-id pub-id-type="doi">10.1017/S1041610215002082</pub-id><pub-id pub-id-type="pmid">26744954</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>C</given-names></name><name name-style="western"><surname>Shaheen</surname><given-names>AA</given-names></name><name name-style="western"><surname>Congly</surname><given-names>SE</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>CN</given-names></name><name name-style="western"><surname>Moayyedi</surname><given-names>P</given-names></name><name name-style="western"><surname>Forbes</surname><given-names>N</given-names></name></person-group><article-title>Interpreting reported risks associated with use of proton pump inhibitors: residual confounding in a 10-year analysis of national ambulatory data</article-title><source>Gastroenterology</source><year>2020</year><volume>158</volume><issue>3</issue><fpage>780.e3</fpage><lpage>782.e3</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2019.10.023</pub-id><pub-id pub-id-type="pmid">31678304</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gray</surname><given-names>SL</given-names></name><name name-style="western"><surname>Walker</surname><given-names>RL</given-names></name><name name-style="western"><surname>Dublin</surname><given-names>S</given-names></name><name name-style="western"><surname>Yu</surname><given-names>O</given-names></name><name name-style="western"><surname>Bowles</surname><given-names>EJA</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Proton pump inhibitor use and dementia risk: prospective population-based study</article-title><source>J Am Geriatr Soc</source><year>2018</year><volume>66</volume><issue>2</issue><fpage>247</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1111/jgs.15073</pub-id><pub-id pub-id-type="pmid">29134629</pub-id><pub-id pub-id-type="pmcid">PMC5809315</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liang</surname><given-names>M</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C</given-names></name><name name-style="western"><surname>Song</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>C</given-names></name><name name-style="western"><surname>Shi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Proton pump inhibitors use and dementia risk: a meta-analysis of cohort studies</article-title><source>Eur J Clin Pharmacol</source><year>2020</year><volume>76</volume><issue>2</issue><fpage>139</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1007/s00228-019-02753-7</pub-id><pub-id pub-id-type="pmid">31748819</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>MA</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Iqbal</surname><given-names>U</given-names></name><name name-style="western"><surname>Kamal</surname><given-names>S</given-names></name><name name-style="western"><surname>Khan</surname><given-names>M</given-names></name><name name-style="western"><surname>Khan</surname><given-names>Z</given-names></name><etal/></person-group><article-title>No association linking short-term proton pump inhibitor use to dementia: systematic review and meta-analysis of observational studies</article-title><source>Am J Gastroenterol</source><year>2020</year><volume>115</volume><issue>5</issue><fpage>671</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.14309/ajg.0000000000000500</pub-id><pub-id pub-id-type="pmid">31895707</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desai</surname><given-names>M</given-names></name><name name-style="western"><surname>Nutalapati</surname><given-names>V</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>S</given-names></name><name name-style="western"><surname>Fathallah</surname><given-names>J</given-names></name><name name-style="western"><surname>Dasari</surname><given-names>C</given-names></name><name name-style="western"><surname>Chandrasekhar</surname><given-names>VT</given-names></name><etal/></person-group><article-title>Proton pump inhibitors do not increase the risk of dementia: a systematic review and meta-analysis of prospective studies</article-title><source>Dis Esophagus</source><year>2020</year><volume>33</volume><issue>10</issue><fpage>doaa041</fpage><lpage>doaa041</lpage><pub-id pub-id-type="doi">10.1093/dote/doaa041</pub-id><pub-id pub-id-type="pmid">32476013</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>YQ</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>SL</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J</given-names></name><name name-style="western"><surname>Feng</surname><given-names>SY</given-names></name></person-group><article-title>Proton pump inhibitor use does not increase dementia and Alzheimer's disease risk: an updated meta-analysis of published studies involving 642305 patients</article-title><source>PLoS One</source><year>2019</year><volume>14</volume><issue>7</issue><elocation-id>e0219213</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0219213</pub-id><pub-id pub-id-type="pmid">31265473</pub-id><pub-id pub-id-type="pmcid">PMC6605652</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>J</given-names></name><name name-style="western"><surname>Bao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><name name-style="western"><surname>Tan</surname><given-names>L</given-names></name></person-group><article-title>Possible dementia risk of proton pump inhibitors and H2 receptor blockers use in the treatment of Helicobacter pylori: a meta-analysis study</article-title><source>Med Hypotheses</source><year>2020</year><volume>144</volume><fpage>109989</fpage><lpage>109989</lpage><pub-id pub-id-type="doi">10.1016/j.mehy.2020.109989</pub-id><pub-id pub-id-type="pmid">32563971</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>